TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02508389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.~Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.~Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.~Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor
Study: NCT04042792

Intervention type: OTHER
Intervention: pharmacokinetics (PK) measurement
Description: two ADA-PK samples will be collected during routine rheumatology visits in case of medical indicated blood draw (1 trough PK sample and 1 random PK sample per subject)

Intervention type: OTHER
Intervention: pharmacokinetics (PK) measurement
Description: two ADA-PK samples will be collected during routine rheumatology visits in case of medical indicated blood draw (1 trough PK sample and 1 random PK sample per subject)
Study: NCT01481467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccination implementation strategy
Description: A multi-faceted influenza vaccination implementation strategy
Study: NCT03186664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat training
Description: The neurorobotic treatment will be performed by using the Lokomat (Lokomat, Hocoma, Volketswil, Switzerland) device. The work load will be progressively adjusted based on the improvement of motor performances. Training parameters (weight support, etc) will be individually adapted. During the first Lokomat session, support will be set at 50% of the body weight and will be adapted on observation of the gait. The Lokomat motor guidance system will be first set at 100%, corresponding to a passive walk.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lokomat training
Description: The neurorobotic treatment will be performed by using the Lokomat (Lokomat, Hocoma, Volketswil, Switzerland) device. The work load will be progressively adjusted based on the improvement of motor performances. Training parameters (weight support, etc) will be individually adapted. During the first Lokomat session, support will be set at 50% of the body weight and will be adapted on observation of the gait. The Lokomat motor guidance system will be first set at 100%, corresponding to a passive walk.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Patients in treatment with Sativex will receive cannabis-based medicine extract presented in a pump action sublingual spray. Sativex is composed of whole cannabis plant extract, containing THC (27 mg/mL) and CBD (25 mg/mL), in ethanol/propylene glycol (50:50) excipient.~Each actuation delivers 100 KL of spray, containing THC 2.7 mg and CBD 2.5 mg. The number and frequency of dosing (sprays) with Sativex will vary from individual to individual and it may take a number of weeks to find the correct dose of Sativex for the individual patient.
Study: NCT01869374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagVenture MagPro MST
Description: Brain stimulation by magnetic means versus electrical standard unilateral Electroconvulsive Therapy (RUL ECT). Treatment will be administered 3 times a week.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RUL ECT
Description: RUL ECT using the Somatics Thymatron device with Ultrabrief stimulus. Treatment will be administered 3 times a week.
Study: NCT02298660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: BOTOX® Total dose per patient: 200U Number of cycles:1 cycle~200 units of BOTOX® will be injected per procedure. BOTOX® will be diluted in 15mL saline to 20U/mL. BOTOX® injections will be performed with a normal 22 FF rigid cystoscopy or flexible 6Fr injection needle. BOTOX® will be injected into the detrusor muscle at 20 sites (10U per site), sparing the trigone. A local anaesthesia with instillation of 50 ml lidocaine 2% into the bladder will be done prior to the procedure to avoid autonomic dysreflexia.
Study: NCT02392910

Intervention type: DRUG
Group type: OTHER
Intervention: Iron Sucrose
Description: At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag contained 200 ml isotonic saline solution 0.9% plus 200 mg of Iron Sucrose. Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag of isotonic saline solution 0.9% (200 ml). Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
Study: NCT02032485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: An iv injection will be performed for the colorectal cancer patient before the operation.
Study: NCT02912052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peri-operative chemotherapy
Description: Patients receive 2 cycles of chemotherapy before surgery,and contniue to receive another 4 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: postoperative chemotherapy
Description: Patients receive 6 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
Study: NCT02145650

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention administered in this study.
Study: NCT00851162

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trinity multipotent stem cells
Description: Enough to fill voids which vary in size

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Demineralized bone matrix(DBM)
Description: Enough DBM to fill a bone void defect
Study: NCT00627276

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: Oral, 3 times daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral, 3 times daily
Study: NCT00243841

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation
Description: Arm A: Childs A - receive 3 fractions. Arm B: Childs B - receive 5 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation
Description: Arm A: Childs A - receive 3 fractions. Arm B: Childs B - receive 5 fractions.
Study: NCT02980575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT00285389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriblastin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alkeran

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total body irradiation (8Gy/4fr)
Study: NCT05532878

Intervention type: DRUG
Intervention: Apixaban
Description: Apixaban 2.5 mg daily
Study: NCT01303419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CE-BMRI
Description: Contrast-enhanced breast imaging using Magnetic Resonance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DE-CEDM
Description: Breast imaging using Dual-energy, contrast-enhanced digital mammography
Study: NCT00782444

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computer navigated knee replacement
Description: Total knee replacement performed with the use of navigation system from Brainlab with the Profix total knee implant.
Study: NCT00285389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 0,4 mg/day day 1 to day 4
Study: NCT02863536

Intervention type: DEVICE
Group type: OTHER
Intervention: Polybactum®
Description: 3 cycles treatment one per month.. Duration of one cycle: 1 week; administration for each cycle: 1 ovule at Day 1, 1 ovule at Day 4; 1 ovule at Day 7.In the two following cycles, the same treatment will be repeated immediately after the end of the first and second menstrual bleeding.
Study: NCT01981551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: Treatment with the selective small-molecule \>=-secretase inhibitor PF- 3084014 caused significant tumor shrinkage in patients with unresectable desmoid tumors in an early-phase clinical trial.
Study: NCT00782444

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional knee replacement
Description: Conventional total knee replacement performed in a traditional way with the use of intramedullary rods, with the Profix implant.
Study: NCT02513875

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: 60,000 IU per week for 8 weeks
Study: NCT00960570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz 600 mg
Description: Efavirenz 600 mg administered as a single oral dose on the morning of Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg
Description: Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric Acid
Description: Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
Study: NCT04180540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Closure
Description: The PerClose Proglide system will be used to deliver a suture to close the venous puncture following completion of ablation for treatment of atrial fibrillation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Compression
Description: Manual compression is the standard method of attaining hemostasis following ablation for treatment of atrial fibrillation. Manual compression may be performed with or without figure of eight suture for hemostasis at the discretion of the treating physician).
Study: NCT01589991

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Toothpaste
Description: The volunteers brushed their teeth with 0.3 g of the assigned toothpastes, 3x/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste
Description: The volunteers brushed their teeth with 0.3 g of the assigned toothpastes, 3x/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste
Description: The volunteers brushed their teeth with 0.3 g of the assigned toothpastes, 3x/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste
Description: The volunteers brushed their teeth with 0.3 g of the assigned toothpastes, 3x/day.
Study: NCT03939741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVF Containg Autologous Non Expanded ADSC
Description: 5 ml of SVF containing Autologous Non Expanded ADSC will be injected intravenously and outcome will be observed over the period of 1(one) year.
Study: NCT01808092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftazidim-avibactam (CAZ-AVI, experimental product)
Description: 2000mg ceftazidime plus 500mg avibactam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem (active comparator)
Description: 1000mg of Meropenem
Study: NCT04894331

Intervention type: OTHER
Intervention: Dietary intervention
Description: Each patient receives one of 5 dietary plans, different only for energy intake (1400-1600-1800-2000-2100 Kcal/day). The choice depends on the personalized energy needs. The energy requirement is calculated on basal metabolic rate (BMR) of the patient according to Harris \& Benedict's and Schofield's formulas.~All dietary plans include foods with low-Ni content. Finally, each patient completes 30-day personalized diet.
Study: NCT02513875

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo +diet and lifestyle
Study: NCT01510639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: The application of autologous thrombocyte concentrate (PRP). This is a concentrate with a high amount of thrombocytes (containing growth factors), obtained by centrifuging the patient's own blood. The concentrate is applied into the subacromial space after closure.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: The application of autologous thrombocyte concentrate (PRP). This is a concentrate with a high amount of thrombocytes (containing growth factors), obtained by centrifuging the patient's own blood. The concentrate is applied into the subacromial space after closure.
Study: NCT02456064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: * Group medical visits~* Telephone medical consultations~* Expert patient~* Training workshops
Study: NCT04894331

Intervention type: OTHER
Intervention: Video call
Description: Each patient receives a follow-up remote visit through video call 15 and 30 days after the start of the dietary intervention.
Study: NCT01937832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faropenem
Description: dosage form: Injection dosage:1200 mg frequency: Three times a day
Study: NCT03149770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone then placebo
Description: naloxone intranasal 4mg, then placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo then Naloxone
Description: placebo then naloxone intranasal 4mg
Study: NCT00332397

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin-eluting Stent
Description: due to randomization, Cypher stent will be implanted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus-eluting Stent
Description: due to randomization, Endeavor stent will be implanted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin-eluting Stent
Description: due to randomization, rapamycin-eluting stent will be implanted
Study: NCT01644838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine
Description: The samples were randomly allocated to inject of 20 mg of hyoscineIM in dilatation 3-5cm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine
Description: The samples were randomly allocated to inject of 25 mg of promethazine IM in dilatation 3-5cm.
Study: NCT00448045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual and mechanical assisted cough
Description: Individuals will be given a pulse oximeter and taught both manually assisted and mechanically assisted coughing techniques to maximize their cough. Manually assisted coughing consists of air stacking to deep insufflations. An abdominal thrust is then applied upon glottic opening to augment the cough. These subjects will also have rapid access to a mechanical in-exsufflator (CoughAssistTM) and will be trained on how to access and use this device. Mechanically assisted coughing (MAC) involves the use of the CoughAssistTM to expand the lungs and then quickly reverse the pressure to rapidly empty the lungs with expiratory (cough) flows of 600 L/m. An abdominal (manual) thrust is applied in conjunction with the negative pressure (exsufflation) to further increase cough.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentive spirometry
Description: These individuals will be given a pulse oximeter and an incentive spirometer (AirLife Company) and taught how to use them.
Study: NCT02543411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Description: Intravenous administration as bolus of lidocaine 1.5 mg/kg before sedation and infusion of lidocaine 2 mg/kg/hr during sedation.~Sedation with fentanyl and propofol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intravenous administration as bolus of normal saline 0.15 mL/kg before sedation and infusion of normal saline 0.2 mL/kg/hr during sedation.~Sedation with fentanyl and propofol
Study: NCT03890965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflex locomoction therapy
Description: The intervention of the stimulation of the reflex locomotion is carried out in this study in a sitting position in a conventional chair, an unorthodox posture in the usual treatment of Vojta therapy.~The reflex stimulation is performed by the passive pressure exerted by the weight of the wrist (pisiform) on the rubber sphere. Simultaneously the patient has to exert a slight pressure with the heel towards the ground with his foot. This foot will be the opposite of the wrist that has the sphere under the pisiform.~Alternating each diagonal 4 times, 5 minutes each. Total session 20 minutes, 2 times x day, every day according to degree of affectation.
Study: NCT03716427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT1812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolbutamide
Description: Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of tolbutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan
Description: Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of dextromethorphan
Study: NCT01937832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: dosage form: Injection dosage:1000 mg frequency: once a day
Study: NCT03716427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of midazolam
Study: NCT04898556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasterone 6.5 MG
Description: The dose to be applied will be one Intrarosa ovule (Prasterone 6.5mg) a day before going to bed for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with a diagnosis of VVA who will not undergo treatment for 12 weeks.
Study: NCT04492670

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tui-na
Description: For administering of Tui-na manipulation practice, responsible Tui-na CMP must have at least 2 years of clinical experience. The pre-trial workshops led by a senior practitioner will be organized to ensure standardization of Tui-na treatment manipulation and procedures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tui-na
Description: For administering of Tui-na manipulation practice, responsible Tui-na CMP must have at least 2 years of clinical experience. The pre-trial workshops led by a senior practitioner will be organized to ensure standardization of Tui-na treatment manipulation and procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Du-Huo-Ji-Sheng-Tang (DHJST)
Description: This study medication is derived from Du-Huo-Ji-Sheng-Tang (DHJST) and concentrated Chinese Medicine granules will be used.
Study: NCT04490460

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: WBF-0031
Description: Medical food formulation WBF-0031

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: WBF-0031
Description: Medical food formulation WBF-0031
Study: NCT01698788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Drug delivery system (Ozurdex)
Description: It is a sustained release intravitreal implant containing 700µg dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Drug delivery system (Ozurdex)
Description: It is a sustained release intravitreal implant containing 700µg dexamethasone
Study: NCT01336270

Intervention type: OTHER
Intervention: biological collection
Description: to collect some human cell samples in melanoma

Intervention type: OTHER
Intervention: biological collection
Description: to collect some human cell samples in melanoma

Intervention type: OTHER
Intervention: biological collection
Description: to collect some human cell samples in melanoma

Intervention type: OTHER
Intervention: biological collection
Description: to collect some human cell samples in melanoma
Study: NCT02081326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin
Description: 2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: 2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
Study: NCT03120351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm 5 % Topical Patch
Description: Patients will receive Lidoderm topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: 2) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off
Study: NCT03231878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MIN-102
Description: MIN-102 treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study: NCT03253861

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention